Global Biomarkers Market Outlook to 2028

Global Biomarkers Market Overview

The global biomarkers market is valued at USD 79.8 billion in 2023, driven by increasing investments in precision medicine, the rise in chronic diseases, and the growth of personalized therapies. Biomarkers are essential in early diagnosis, aiding in improving patient outcomes, especially for cancer, cardiovascular diseases, and neurological conditions. This growth is accelerated by pharmaceutical companies adopting biomarkers to enhance the efficacy of drugs and reduce development time, contributing significantly to market expansion.

Key players dominating the global biomarkers market include Roche Diagnostics, Thermo Fisher Scientific, Abbott Laboratories, Qiagen N.V., and Siemens Healthineers. These companies are at the forefront of innovations, regularly launching new biomarker assays and platforms. For instance, Roche Diagnostics holds a large share due to its advanced oncology and cardiology biomarker portfolios. Collaborations between these players and healthcare institutions for clinical trials and research are further driving their market leadership.

In May 2023, Thermo Fisher Scientific and Pfizer announced a partnership aimed at expanding access to next-generation sequencing (NGS)-based testing for lung and breast cancer patients in over 30 countries, particularly in regions where such advanced genomic testing has been limited or unavailable. The collaboration's goal is to enhance local access to these testing capabilities, which can provide faster results and potentially improve patient outcomes.

Major cities such as Boston, San Francisco, and Basel dominate the biomarkers market due to their dense concentration of biotechnology firms, pharmaceutical giants, and advanced research institutions. Boston, home to prominent medical schools and research hospitals, has seen significant advancements in cancer biomarkers, while San Franciscos robust biotech ecosystem supports innovation in neurological biomarkers. Basel, Switzerland, hosts Roches headquarters, a leader in oncology biomarkers, contributing to its dominance.

Global Biomarkers Market Segmentation

The Global Biomarkers Market is divided into the following segments:

By Biomarker: The global biomarkers market is segmented by biomarker types into safety biomarkers, efficacy biomarkers, and validation biomarkers. In 2023, safety biomarkers dominated the market, driven by their extensive use in drug development. Pharmaceutical companies rely heavily on safety biomarkers to assess the toxicity and safety of new drugs, ensuring compliance with regulatory standards. Efficacy biomarkers are also gaining importance, particularly in precision medicine, where they help monitor therapeutic responses and optimize treatment outcomes.

By Region: The global biomarkers market is segmented by region into North America, Europe, Asia- Pacific (APAC), Latin America, and the Middle East & Africa (MEA). In 2023, North America held the largest market share due to the presence of key players, advanced healthcare infrastructure, and substantial R&D investments. The U.S., in particular, is leading the biomarker market, driven by government initiatives such as the Precision Medicine Initiative and the dominance of biotech hubs like Boston and San Francisco. Europe, led by Germany and the UK, also holds a significant share.

By Application: The global biomarkers market is segmented by application into oncology, cardiology, and neurology. In 2023, oncology biomarkers dominated the market, capturing the largest share due to the rapid adoption of biomarkers in cancer diagnostics and therapeutics. Companies such as Roche Diagnostics are leveraging oncology biomarkers to develop companion diagnostics for cancer drugs, helping clinicians personalize treatments. The rising prevalence of cancer, along with increased funding for cancer research, has contributed significantly to the growth of this segment.

Global Biomarkers Market Competitive Landscape

Company

Establishment Year

Headquarters

Roche Diagnostics

1896

Basel, Switzerland

Thermo Fisher Scientific

1956

Waltham, Massachusetts, USA

Abbott Laboratories

1888

Illinois, USA

Qiagen N.V.

1984

Hilden, Germany

Siemens Healthineers

2018

Erlangen, Germany

Thermo Fisher Scientific: Thermo Fisher, in collaboration with Pfizer, introduced a non-small cell lung cancer (NSCLC) biomarker test in 2023. This collaboration is aimed at accelerating the adoption of companion diagnostics in lung cancer, which accounts for a significant share of cancer biomarker applications. The new test, combined with Pfizer's therapies, is expected to improve patient outcomes in NSCLC.

Abbott Laboratories: In 2024, Abbott announced the expansion of its biomarker testing capabilities in cardiovascular disease. By leveraging their i- STAT handheld device, they aim to bring point-of-care biomarker testing to more hospitals globally. This expansion is anticipated to improve the early diagnosis of cardiovascular diseases, reducing treatment costs and enhancing patient outcomes.

Global Biomarkers Market Analysis

Global Biomarkers Market Growth Drivers

Expansion in Precision Medicine Initiatives: The growing focus on precision medicine, especially for oncology and cardiovascular diseases, is a major driver for the biomarker market. The global push for more personalized treatment plans is directly increasing the demand for biomarkers in diagnostics and treatment monitoring. For instance, in 2023, the Precision Medicine Initiative in the U.S. aims to enroll one million patients into studies incorporating genetic biomarkers to identify optimal treatment options. These initiatives are contributing to the higher adoption of biomarkers across various healthcare systems worldwide.

Rising Prevalence of Chronic Diseases: In 2023, the World Health Organization reported that chronic diseases such as cancer, diabetes, and cardiovascular conditions were a leading cause of global mortality. This rise in chronic diseases has significantly boosted the demand for biomarkers, which are essential for early diagnosis and personalized treatment. For example, cancer biomarkers help in detecting malignancies at earlier stages, which can lead to better patient outcomes. The increasing number of patients needing long-term disease management drives biomarker research and development, particularly in diagnostics.

Increasing Investments in Clinical Research: Governments worldwide have been significantly increasing their budgets for medical research, particularly in biomarker technologies. In 2023, the U.S. government allocated$6 billiontowards cancer research under the Cancer Moonshot Initiative. This initiative emphasizes biomarker-driven studies, which are crucial for advancing personalized medicine and improving cancer treatment outcomes. The focus on biomarkers is particularly relevant for identifying effective therapies for various cancer types, thereby enhancing precision medicine efforts.

Global Biomarkers Market Challenges

High Costs Associated with Biomarker Development: Biomarker discovery and validation are costly processes, which pose a significant challenge for many organizations. Developing a single biomarker can cost millions of dollars and take several years to complete. For instance, the average cost for developing a biomarker for cancer diagnosis is estimated to be around $100 million. This financial burden limits the number of organizations that can afford extensive research and development, thereby restricting the availability of new biomarkers in the market.

Limited Biomarker Validation for Neurological Disorders: Although there has been rapid progress in biomarker discovery for diseases like cancer and cardiovascular conditions, biomarkers for neurological diseases are still underdeveloped. In 2023, only a small number of biomarkers have been validated for major neurological diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). This scarcity complicates the diagnosis and treatment of these conditions.

Global Biomarkers Market Government Initiatives

European Union Horizon Program: The EU launched its Horizon program to support biomarker research in various diseases, including rare genetic conditions and chronic diseases. The initiative focuses on early diagnosis through biomarkers and improving therapeutic options through personalized medicine. Several European countries, such as Germany and France, are collaborating with biotech firms to discover novel biomarkers, particularly in oncology.

Japans Government Funding for Cancer Biomarkers: In 2023, the Japanese government announced a $1 billion investment to fund biomarker research for cancer diagnosis and treatment. This initiative is part of Japans broader healthcare reforms aimed at improving cancer survival rates. The funding will be directed toward developing biomarker-based diagnostic tools for early-stage cancer detection, contributing to Japans goal of significantly reducing cancer-related mortality in the coming years.

Global Biomarkers Market Outlook

The global biomarkers market is set to experience significant growth over the next five years, primarily driven by advancements in personalized medicine. As healthcare systems continue to shift toward individualized treatment plans, biomarkers are playing a crucial role in diagnostics, drug development, and patient care.

Future Trends:

Growth of Biomarker- Based Companion Diagnostics: By 2028, the demand for biomarker-based companion diagnostics is projected to increase, especially in oncology and cardiology. The integration of biomarkers into clinical trials and drug development will reduce drug failure rates and improve the efficacy of treatments. With pharmaceutical companies investing heavily in this area, companion diagnostics will likely become a mainstream approach in treatment protocols for several chronic diseases.

Increased Focus on Multi- Omics Approaches: In the future, multi-omics approaches that combine genomic, proteomic, and metabolomic biomarkers are anticipated to dominate the market. These approaches will enable a more comprehensive understanding of diseases and enhance the accuracy of diagnostics and treatment plans. Governments are expected to fund multi-omics research, particularly in regions like Europe and North America, making it a key driver of market growth by 2028.
Please Note: It will take 5-7 business days to complete the report upon order confirmation